Breast Cancer


Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR).

Trial overview


Breast cancer


This study will investigate the safety and efficacy of Stereotactic Radiotherapy treatment in combination with aromatase inhibitor and cyclin-dependent kinase (CDK) 4/6 inhibitor for metastatic breast cancer." You may be eligible to join this study if you are aged 18 and above, have histologically proven ER-positive, HER2-negative advanced breast cancer with metastases and receiving an aromatase inhibitor in combination with a CDK 4/6 inhibitor.

Eligibility criteria

Patients with ER-positive, HER2-negative advanced breast cancer receiving an AI in combination with a CDK 4/6 inhibitor with ≤ 5 sites of oligoprogressive disease amenable to SRT.

Study details

Patients must have evidence of response to AI and CDK 4/6 inhibitor for a minimum of six months prior to study entry (defined as either stable disease or partial response).

Patients will receive SRT to all sites of Oligoprogressive disease while continuing on AI and CDK 4/6 inhibitors.

Further information

For more information regarding this clinical trial click here.

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.